TY - JOUR

T1 - Factors to Consider in Prescribing Asthma Biologic Therapies to Children

AU - Anderson, William C.

AU - Banzon, Tina M.

AU - Chawes, Bo

AU - Papadopoulos, Nikolaos G.

AU - Phipatanakul, Wanda

AU - Szefler, Stanley J.

N1 - Publisher Copyright: © 2023 American Academy of Allergy, Asthma & Immunology

PY - 2023

Y1 - 2023

N2 - The increasing availability of biologics, both by expanding age indications and by development of new therapies, provides additional options to treat children and adolescents with severe asthma. However, the evidence for these biologics in these populations is limited compared with that for adult studies. As such, before initiation of therapy, possible alternative therapies that can also provide asthma control, confirmation of the diagnosis of asthma, management of comorbidities, and assessment of adherence should be explored. The choice of a biologic should be a shared decision-making process between providers and families, balancing biologic efficacy, goals of care, administration, and ability to treat multiple conditions. Response to treatment should be periodically evaluated not only to ensure an ineffective treatment is not continued but also to consider when to potentially discontinue therapy should it be beneficial. The utilization of biologics in children and adolescents with severe asthma also leads to unanswered questions on their role in disease remission and long-term outcomes.

AB - The increasing availability of biologics, both by expanding age indications and by development of new therapies, provides additional options to treat children and adolescents with severe asthma. However, the evidence for these biologics in these populations is limited compared with that for adult studies. As such, before initiation of therapy, possible alternative therapies that can also provide asthma control, confirmation of the diagnosis of asthma, management of comorbidities, and assessment of adherence should be explored. The choice of a biologic should be a shared decision-making process between providers and families, balancing biologic efficacy, goals of care, administration, and ability to treat multiple conditions. Response to treatment should be periodically evaluated not only to ensure an ineffective treatment is not continued but also to consider when to potentially discontinue therapy should it be beneficial. The utilization of biologics in children and adolescents with severe asthma also leads to unanswered questions on their role in disease remission and long-term outcomes.

KW - Biologic

KW - Difficult-to-treat asthma

KW - Pediatric asthma

KW - Severe asthma

KW - Therapy

KW - Treatment

U2 - 10.1016/j.jaip.2022.12.038

DO - 10.1016/j.jaip.2022.12.038

M3 - Journal article

C2 - 36646381

AN - SCOPUS:85147284683

VL - 11

SP - 693

EP - 701

JO - The Journal of Allergy and Clinical Immunology: In Practice

JF - The Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 3

ER -